Scalper1 News
Specialty drugmaker Jazz Pharmaceuticals (JAZZ) was up 6% in afternoon trading on the stock market today, at a four-month high near 161, after it inked a deal for the American rights to its recently acquired drug defibrotide. Defibrotide, which treats a rare condition called severe hepatic veno-occlusive disease, was developed by Italian biotech Gentium, which Jazz acquired in February. Gentium had licensed the marketing rights in the Americas to Scalper1 News
Scalper1 News